Opinion on  ACADIA Pharmaceuticals Inc. (ACAD)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Bullish on ACAD ...

        The fundamentals for this company are huge going into future with a big bank balance as of June 30, 2007, ACADIA's cash, cash equivalents, and investment securities totaled $153.9 million and a with a great drugs pipeline thats starting to mature. in dealing with parkinson's and schizophrenia there is a possibility of opening up a huge market 1billion+ market that no one has got a grasp of yet and results so far are good.

       Also out today is an upgrade up target from$18 to $28 http://biz.yahoo.com/ap/071009/acadia_pharma_mover.html?.v=1&... and that could be the tip of ice berg. market cap at $600m  which is small for the potential market it could find itself in , in 2-3 years.

            Program                               INDICATION

• Pimavanserin            - Parkinson’s Disease Psychosis         - phase 3
  
• Pimavanserin            - Schizophrenia                                         - phase 2
  
• Pimavanserin            - Sleep Maintenance Insomnia              - phase 2
• ACP-104                     - Schizophrenia                                         - phase 2b
• AGN XX/YY                 -  Neuropathic Pain                                   - phase 2
• AC-262271                - Glaucoma                                                 - IND-TRACK
• ACP-105                    - Endocrinology                                          - IND-TRACK
• ACP-106                    - Sleep/Neuropsychiatry                           - IND-TRACK
• Serotonin                   - Sleep/Neuropsychiatry                          - PRECLINICAL
• PCAPs                        - Schizophrenia                                        - PRECLINICAL
• Muscarinic                 - Neuropsychiatry/Other                          - PRECLINICAL
• CB1                             - Obesity                                                    - PRECLINICAL